Health Canada Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults and Children with Stage IIB or IIC Melanoma Following Complete Resection

/CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval for KEYTRUDA® (pembrolizumab),...

Related Keywords

United States ,Canada ,Canadians ,Falyn Katz ,Kathy Barnard ,Save Your Skin Foundation ,Health Canada ,Save Your Skin ,Executive Director ,Merck Canada ,